Usefulness of a New Therapy Using Rebamipide Eyedrops in Patients with VKC/AKC Refractory to Conventional Anti-Allergic Treatments

Ueta, Mayumi; Sotozono, Chie; Koga, Ayaka; Yokoi, Norihiko; Kinoshita, Shigeru

doi:10.2332/allergolint.13-oa-0605

Cited by 17 publications

(9 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, Ueta et al recently in Japan conducted a clinical trial of this drug on 4 patients with VKC/AKC refractory to conventional anti-allergic treatment and observed attenuation of the giant papillae in all 4 patients, thereby, for the first time demonstrating the use of this drug for allergic conjunctival diseases. 16 Reported adverse event rates were null in the study. Maximum benefit among all the patients was found by at least 3-5 weeks of treatment with rebamipide 2%.…”

Section: Discussionmentioning

confidence: 73%

Rebamipide 2% Ophthalmic Suspension for the Treatment of Allergic Keratoconjunctivitis: A Hospital Based Study

Dhawan¹

2016

DJO

View full text Add to dashboard Cite

Background: The aim of this study was to evaluate the effectiveness of Rebamipide 2% ophthalmic suspension in the treatment of Allergic Keratoconjunctivitis. Rebamipide 2% ophthalmic suspension has shown to be advantageous for the treatment of dry eye and an improvement of ocular allergic conditions, after its application is also remarkable for the patients, especially in severe conditions. Study was done to report the improvement in signs and symptoms after using Rebamipide 2% as an additional therapy in allergic patients and reduced dependency on topical steroids. Materials and Methods: Rebamipide 2% ophthalmic suspension was used in the treatment of allergic keratoconjunctivitis. We used subjective signs and symptoms of allergic keratoconjunctivitis as well as objective tests of tear film production like TBUT and Schirmer I and compared the post-treatment values at 1 week, 3 weeks, 5 weeks and 7 weeks, with baseline values. Results: The study revealed that Rebamipide 2% significantly improved the clinical grading of the disease, Schirmer I and Tear Film Breakup Time (TBUT) scores. No significant side effects to the therapy were observed. In steroid responsive patients, no aggravation of symptoms was observed after tapering the dose of steroids while steroid non-responder patients showed a significant improvement in the clinical signs and symptoms of allergic keratoconjunctivitis. Maximum effect was observed at 5 weeks of initiation of therapy. Conclusion: Rebamipide 2% is effective in improving the signs and symptoms of allergic ocular diseases and is well-tolerated. It helps in reducing the dependence on steroids for the treatment of allergic keratoconjunctivitis.

show abstract

Section: Discussionmentioning

confidence: 73%

Rebamipide 2% Ophthalmic Suspension for the Treatment of Allergic Keratoconjunctivitis: A Hospital Based Study

Dhawan¹

2016

DJO

View full text Add to dashboard Cite

show abstract

“…Some patients with allergic conjunctival diseases present with dry eye, which is the type of a decrease in the tear break-up time (BUT) [ 9 , 10 ]. We found that rebamipide suppressed polyI:C-induced inflammatory cytokines in human conjunctival epithelial cells [ 11 ] and suggested that the combination of rebamipide eyedrops and conventional anti-allergic treatments might be effective in patients with vernal/atopic keratoconjunctivitis (VKC, AKC) refractory to conventional treatment with anti-allergic- and/or immunosuppressive/steroid eyedrops [ 12 ].…”

Section: Resultsmentioning

confidence: 99%

Downregulation of IL‐8, ECP, and total IgE in the tears of patients with atopic keratoconjunctivitis treated with rebamipide eyedrops

Ueta

Shoji

Sotozono

et al. 2014

Clinical & Translational All

Self Cite

View full text Add to dashboard Cite

Rebamipide eyedrops are approved in Japan for the treatment of dry eye disease. Some patients with allergic conjunctival diseases also manifest dry eye. Earlier we reported that rebamipide suppressed polyI:C-induced inflammatory cytokines in human conjunctival epithelial cells. In the current study we examined the effect of rebamipide eyedrops on the level of interleukin-8 (IL-8), eosinophil cationic protein (ECP), and total IgE on the ocular surface.We prescribed rebamipide eyedrops to patients with atopic keratoconjunctivitis (AKC) who presented with dry eye (6 eyes in 4 AKC patients) and measured the IL-8, ECP, and total IgE levels in their tears before- and 2, and 4–6 weeks after the start of rebamipide treatment. To measure the IL-8 and total IgE levels in their tears we used BD™ CBA Flex sets; ECP measurements were with ELISA. The level of IL-8, ECP, and total IgE in the tears of AKC patients was reduced significantly 4–6 weeks after the start of rebamipide treatment. We also recorded subjective symptoms associated with AKC, e.g. itching, foreign body sensation, and eye mucus discharge, by using a patient questionnaire. Their subjective symptoms associated with AKC were also significantly ameliorated at 2 and 4–6 weeks.Our observations suggest that the anti-inflammatory effects of rebamipide eyedrops help to combat human ocular surface inflammation and that they may be a new effective therapy in patients with AKC.Electronic supplementary materialThe online version of this article (doi:10.1186/2045-7022-4-40) contains supplementary material, which is available to authorized users.

show abstract

“…The giant papillae associated with vernal keratoconjunctivitis may therefore develop as a result of the interaction of immune cells and conjunctival fibroblasts. Rebamipide eyedrops were recently shown to ameliorate giant papillae in four patients with vernal keratoconjunctivitis or atopic keratoconjunctivitis 25. The mechanism of this therapeutic effect of rebamipide remains unclear, but it is possible that it is due at least in part to suppression of the function of conjunctival fibroblasts.…”

Section: Discussionmentioning

confidence: 99%

Inhibition by rebamipide of cytokine-induced or lipopolysaccharide-induced chemokine synthesis in human corneal fibroblasts

et al. 2014

View full text Add to dashboard Cite

show abstract

Usefulness of a New Therapy Using Rebamipide Eyedrops in Patients with VKC/AKC Refractory to Conventional Anti-Allergic Treatments

Abstract: Our findings suggest that rebamipide eyedrops might attenuate giant papillae in patients with allergic conjunctival diseases and that these eyedrops may be useful for the treatment of not only dry eye but also of allergic conjunctival diseases.

Cited by 17 publications

References 11 publications

Rebamipide 2% Ophthalmic Suspension for the Treatment of Allergic Keratoconjunctivitis: A Hospital Based Study

Rebamipide 2% Ophthalmic Suspension for the Treatment of Allergic Keratoconjunctivitis: A Hospital Based Study

Downregulation of IL‐8, ECP, and total IgE in the tears of patients with atopic keratoconjunctivitis treated with rebamipide eyedrops

Inhibition by rebamipide of cytokine-induced or lipopolysaccharide-induced chemokine synthesis in human corneal fibroblasts

Contact Info

Product

Resources

About